Short Interest in I-Mab Sponsored ADR (NASDAQ:IMAB) Increases By 38.8%Market Beat·Nov 4, 2025 at 05:46 PMIMAB0.00%
I-Mab's (IMAB) Sell (D-) Rating Reaffirmed at Weiss RatingsMarket Beat·Nov 1, 2025 at 12:13 PMIMAB0.00%
NovaBridge Biosciences Unveils New Identity and Strategic DirectionTip Ranks·Oct 29, 2025 at 03:32 PMIMAB0.00%NBP-1.69%
I-MAB Completes Acquisition of Bridge Health BiotechTip Ranks·Oct 28, 2025 at 03:44 PMIMAB0.00%NBP-1.69%
I-Mab Sponsored ADR (NASDAQ:IMAB) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarket Beat·Oct 28, 2025 at 04:26 AMIMAB0.00%NBP-1.69%
Promising Clinical Data and Strategic Uncertainties: Analyst Recommends ‘Buy’ for I-MABTip Ranks·Oct 27, 2025 at 05:26 AMIMAB0.00%NBP-1.69%
I-Mab Rebrands to NovaBridge Biosciences Following Shareholder ApprovalTip Ranks·Oct 24, 2025 at 03:50 PMIMAB0.00%NBP-1.69%
I-MAB Releases Promising Phase I Data for Givastomig in Advanced Gastric CancerTip Ranks·Oct 24, 2025 at 11:57 AMIMAB0.00%NBP-1.69%
